OSTX OS Therapies Incorporated

AMEX
$1.62

OS Therapies Incorporated (OSTX) is expected to report earnings on November 13, 2026, before the market open. The consensus earnings estimate is a loss of $0.24 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +2.5% since its last earnings release on August 14, 2026.

OS Therapies Beat Consensus Estimates
Earnings Date
3rd Quarter, Sep 2026
Nov 13
Friday · Before Open
Earnings Whisper
-
vs ($0.24)
Rev est $999
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.77

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About OS Therapies Incorporated

OS Therapies Incorporated is a clinical stage oncology company focused on the identification, development and commercialization of treatments for Osteosarcoma and other solid tumors. The company's lead asset consists OST-HER2. OS Therapies Incorporated is based in NEW YORK.

Sector

Healthcare

Industry

Biotechnology